



Extraordinary General Meeting of Kuros Biosciences approves all resolutions

July 17, 2019

Schlieren (Zurich), Switzerland, July 17, 2019 – Kuros Biosciences (SIX:KURN) today announced that its Extraordinary General Meeting approved all resolutions proposed by the Board of Directors

Shareholders resolved on an increase and adjustment of the authorized share capital (up to 4,000,000 registered shares with a nominal value of CHF 1.00 each) and the conditional share capital for Employee Participation (up to 2,248,389 registered shares with a nominal value of CHF 1.00 each). They also resolved an increase and adjustment of the Conditional Share Capital for bonds and similar debt instruments (up to 4,000,000 registered shares with a nominal value of CHF 1.00 each), and corresponding changes to the Articles of Incorporation.

The Extraordinary General Meeting took place at the Company's headquarters in Schlieren. It was attended by 32 shareholders. 7,909,950 shares or 52.0% of a total of 15,203,786 shares were represented.

About Kuros Biosciences AG

Kuros Biosciences is focused on the development of innovative products for tissue repair and regeneration and is located in Schlieren (Zurich), Switzerland, Bilthoven, The Netherlands and Burlington (MA), U.S.A. The Company is listed according to the International Financial Reporting Standard on the SIX Swiss Exchange under the symbol KURN. Visit www.kurosbio.com for additional information on Kuros, its science and product pipeline.

Forward Looking Statements

This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words "will" or "expect" or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors. Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.

For further information, please contact:

| | |
|---|-------------------|
| Kuros Biosciences AG | LifeSci Advisors |
| Michael Grau | Hans Herklots |
| Chief Financial Officer | Media & Investors |
| Tel +41 44 733 47 47 | +41 79 598 7149 |
| michael.grau@kurosbio.com hherklots@lifesciadvisors.com | |